Arcturus Therapeutics (ARCT) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Arcturus Therapeutics (ARCT) over the past year, losing 39.5% versus a loss of 50.0%. Arcturus Therapeutics is the larger company by market cap ($293.9 million vs $266.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | CTNM |
|---|---|---|
| Share price | $10.34 | $7.08 |
| Market cap | $293.89M | $266.36M |
| 1-day change | -8.25% | -10.38% |
| YTD return | +68.68% | -38.06% |
| 1-year return | -49.95% | -39.49% |
| 5-year return | -76.77% | — |
| EPS (TTM) | $-3.33 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | — |
| Revenue growth (YoY) | -46.14% | — |
| Net income (latest FY) | $-65.78M | $-59.98M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $24.17 | $17.79 |
| 52-week low | $5.50 | $6.95 |
| Distance from 52-week high | -57.22% | -60.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +130.17% | +212.71% |
| Average volume | 941.87K | 732.62K |
| Shares outstanding | 28.42M | 32.96M |
| Employees | 106 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed ARCT by 10.5 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ARCT vs CTNM FAQ
Which is bigger, Arcturus Therapeutics or Contineum Therapeutics?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $293.89M compared with $266.36M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, ARCT or CTNM?
CTNM returned -39.49% over the past 12 months, compared with -49.95% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.